When innovative therapies make economic sense: Economic analysis of enoxaparin versus unfractionated heparin in the ESSENCE trial - An overview

Canadian Journal of Cardiology

Volumn 14, Issue SUPPL. E18, 1998, Pages

  Mark, Daniel ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY   (United States)

Author keywords

Angina; Anticoagulants; Coronary disease; Economic analysis; Enoxaparin; Low molecular weight heparin

Indexed keywords

ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CORONARY ARTERY DISEASE; DRUG COST; ECONOMICS; FEMALE; HUMAN; MALE; UNITED STATES;

CORONARY DISEASE; DRUG COSTS; ENOXAPARIN; FEMALE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MALE; UNITED STATES;

EID: 0032132522     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (5)

1. Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med 1997;337:447-52.
2. Mark DR. Medical economics in cardiovascular medicine. In: Topol RJ, ed. Textbook of Cardiovascular Medicine. Philadelphia: Lippincott-Raven, 1997:1033-62.
3. Mark DB, Cowper PA, Berkowitz SD, et al. Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients. Results from the ESSENCE randomired trial. Circulation 1998;97:1702-7.
4. Detsky AS, Naglie JG. A clinician's guide to cost-effectiveness analysis. Ann Intern Med 1990;113:147-54.
5. Gold MR, Siegel JE, Russel LR, Weinstein MC. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press, 1996.